MDT-AP-3317
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 5.3
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.032038331
- umap2_2d
- -9.65371915
- umap1_3d
- -3.470840812
- umap2_3d
- -1.049598639
- umap3_3d
- 5.007039098
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- MYC_TARGETS_V1+0.510
- MYC_TARGETS_V2+0.500
- G2M_CHECKPOINT+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.440
- MTORC1_SIGNALING+0.400
- UV_RESPONSE_DN+0.360
- ANDROGEN_RESPONSE+0.320
- CHOLESTEROL_HOMEOSTASIS+0.300
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- HEME_METABOLISM-0.260
- WNT_BETA_CATENIN_SIGNALING-0.180
- KRAS_SIGNALING_DN-0.170
- P53_PATHWAY-0.120
- MYOGENESIS-0.110
- FATTY_ACID_METABOLISM-0.080
- ADIPOGENESIS-0.070
- DNA_REPAIR-0.070
- NOTCH_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.846 |
| 2 | 266354 | EPN | EPN Tumor | 0.837 |
| 3 | TCGA-CV-7440-01A-11R-2132-07 | — | — | 0.821 |
| 4 | MDT-AP-0309 | Med | Medulloblastoma | 0.812 |
| 5 | BS_81SP2HX4 | Med | Medulloblastoma | 0.810 |
| 6 | ERR2208969 | — | — | 0.810 |
| 7 | SRR6013570 | — | cohortSQ1 | 0.807 |
| 8 | afb9b3c2-404f-4d40-8e6e-07b64a295d7e | — | — | 0.801 |
| 9 | MDT-AP-2865 | Med | Medulloblastoma | 0.800 |
| 10 | BS_84XCR9GG | high-grade glioma | — | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |